drugset / Trial / NCT00754052

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052

Phase 3 Terminated 8 enrolled Eisai Inc. Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.

Timeline

Start
2008-09
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 5 mg Oral
Comparator Donepezil Small molecule 10 mg Oral